about our programs

Portage has built a portfolio of six technology platforms initially yielding 14 candidates that uniquely target different cancer resistance pathways.

We’re leading scientists and clinicians through the development of immunotherapies that augment responses in immunogenic tumors and help initiate a response in non-immunogenic tumors. The flagship platform within our portfolio is our small molecule invariant natural killer T-cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Our portfolio also includes small molecule adenosine inhibitors (PORT-6, PORT-7, PORT-8 and PORT-9), which represent a comprehensive exploration of how targeting the adenosine pathway could improve response in multiple indications. See current progress on our programs below.

Pipeline

There is a significant unmet need to better serve patients who do not respond to existing checkpoint inhibitors. We seek novel treatments to improve responses to these therapies. 

iNKT agonists

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60
INDICATION
Melanoma
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Keytruda
INDICATION
Melanoma
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Keytruda
INDICATION
NSCLC
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Cell Therapy
INDICATION
Solid Tumors
STAGE
Preclinical
TECHNOLOGY
iNKT Agonists
Nanoparticle co-formulations
ASSET
(IMM60 / NY-ESO-1) + Keytruda
INDICATION
NY-ESO-1 Positive Tumors
STAGE
Phase I/II

adenosine inhibitors

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
TECHNOLOGY
A2AR Inhibitor
ASSET
TT-10
INDICATION
Solid tumors
STAGE
Phase 1a/1b
TECHNOLOGY
A2BR Inhibitor
ASSET
TT-4
INDICATION
Solid tumors
STAGE
Phase 1a/1b
TECHNOLOGY
A2AR/A2BR Dual Inhibitor
ASSET
TT-53
INDICATION
Solid tumors
STAGE
Preclinical
TECHNOLOGY
Gut-restricted A2BR inhibitor
ASSET
TT-3
INDICATION
Colorectal, GI tumors
STAGE
Preclinical

Additional Programs in Development

Portage’s pipeline also includes antibodies, small molecules and protein therapeutics delivered by novel intratumoral formulations (PORT-1), nanolipogels (PORT-4), and virus-like particles (PORT-5)

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
PORT-1 *
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6
INDICATION
Advanced Soft Tissue Sarcoma
STAGE
Planned Phase III
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6
INDICATION
Early stage breast & solid tumors
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Keytruda
INDICATION
Multiple indications
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 & Yervoy
INDICATION
Multiple indications
STAGE
Phase II
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG 1 (PD1 + VEGF TKI)
INDICATION
Solid Tumors
STAGE
Preclinical
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG2 (PD1 + CTLA4)
INDICATION
Solid Tumors
STAGE
Preclinical
TECHNOLOGY
VLP-STING
ASSET
STIM1 + approved agent
INDICATION
Solid Tumors
STAGE
Preclinical

* Portage Biotech has an 8% economic interest in PORT-1 (INT230-6), which is being advanced in collaboration with Intensity Therapeutics.